Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CLLS - Cellectis
-0.35(-1.11%)9:00:00 PM 1/22/2021
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.
Stock Chart


  • MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics


Stock news

    7 CRISPR Stocks for the Future of Medicine

    In June 2012, the world changed forever. You probably didn’t even notice. It was in that month’s issue of the Science journal that U.C. Berkeley professor Jennifer Doudna and Umea University professor Emmanuelle Charpentier unveiled what the scientific community has since labeled the “scientific breakthrough of the century.” The breakthrough: CRISPR-Cas9 genetic editing systems.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Doudna and Charpentier invented a pair of “scissors” – c...

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting rights 12/31/202042,780,18648,847,575 About Cellectis Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat c...

    Cellectis (CLLS) Jumps: Stock Rises 9%

    Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

    Cellectis Announces Withdrawal of Follow-On Offering

    NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that it has withdrawn the proposed underwritten offering of American Depositary Shares (“ADS”) due to market conditions. The Company believes that it is not in the best interest of its stockholders to raise the equity capital in the current market enviro...

    The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14) * Acceleron Pharma Inc (NASDAQ: XLRN) (announced orphan drug designation for sotatercept in pulmonary arterial hypertension) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Affimed NV (NASDAQ: AFMD) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) - announced a deal to be bought by AstraZeneca plc (NASDAQ: AZN) for $39 billion * Agios Pharmaceutic...

    Cellectis Announces Launch of Follow-On Offering

    NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells, today announced the launch, subject to market conditions, of an underwritten public offering of $100 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis. In connection with the offering, Cellectis ...

    Is CLLS A Good Stock To Buy Now?

    After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]

    Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting

    * Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease * 2 out of 3 Patients at DL1 Achieved CR/CRi and 1 out of 2 Patients at DL2 Achieved a Significant Reduction in Bone Marrow Blasts * BALLI-01 Currently Enrolling at DL2 with Addition of Alemtuzumab to the FC Lymphodepletion Regimen; Next Data Update Expected in 2021NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Grow...